AVITA MEDICAL, INC.

ARBN 641 288 155

Results for announcement to the market

Financial Results (in thousands)				**June 2026**	**June 2025**
Total revenue	Up	11%	to	$ 40,953	$ 36,932
Other income	Down	83%	to	293	1,693
Net loss	Down	23%	to	18,274	23,779
Total other comprehensive loss for the period	Down	29%	to	16,989	23,919

Dividends	**Amount per ordinary security**	**Franked amount per security**
2026 interim dividend	Nil	Nil
2025 interim dividend	Nil	Nil

Record date for determining entitlements to the 2024 interim dividends	N/A

Net Tangible Asset Backing	**June 2026**	**June 2025**
Net tangible asset backing per ordinary security	$ (1.1558)	$ (0.7999)

Other explanatory notes

	June 2026	**June 2025**
Net Tangible Assets:		
Net assets	$ (27,839,723)	$ (12,847,338)
Right of use assets	(2,654,955)	(3,132,197)
Intangibles	(5,249,126)	(5,308,140)
Total net tangible assets	$ (35,743,805)	$ (21,287,674)
Number of ordinary shares on issue	30,926,847	26,613,678
Net tangible asset backing per ordinary security	$ (1.1558)	$ (0.7999)

Additional information

Improved RECELL utilization and new product growth

Reduction in operating losses during the 1H of 2026 reflecting the Company's revenue growth and cost cutting measures

An increase in liabilities due to debt refinancing in support of growth

Reduction in net loss as the Company focuses on cash flow break even and profitability in 2026 and 2027, respectively

Additional disclosure and further commentary on these results is contained in the attached Form 10-Q for the three months and six months ended June 30, 2026